Participate in polls relating to real-time continuous glucose monitoring and see how your answers relate to your colleagues.

The PROMISE study, published in Diabetes Technology & Therapeutics in February 2022, was completed in order to evaluate:
a. Accuracy and safety of a next generation 90-day CGM system
b. Accuracy and safety of the next-generation implantable CGM system for up to 180 days
c. People with diabetes' need of an implantable CGM system for up to 180 days
d. None of the above

Submit is supported by independent educational grants from Ascensia Diabetes Care, Insulet Corporation, Madrigal Pharmaceuticals and Stanford University.
©2023 CogniMed Inc. All rights reserved.